Skip to main content
. 2009 Jul 20;27(24):3881–3886. doi: 10.1200/JCO.2008.20.1566

Fig 3.

Fig 3.

The effect of any TOP2A abnormality (either TOP2A deletion or TOP2A amplification) on disease-free survival for high-level HER2-amplified instances (HER2/CEP17 ratio > 4.0). Similarly, no significant differences in overall survival were observed for TOP2A and HER2 coamplified instances, and neither overall nor disease-free survivals were significantly different when the analysis was segregated for TOP2A deletion or TOP2A amplification within the HER2-amplified group.